Allogene Therapeutics (ALLO) Income from Continuing Operations (2018 - 2026)

Allogene Therapeutics has disclosed Income from Continuing Operations across 9 years of filings, most recently posting 42819000.0 for Q1 2026.

• Income from Continuing Operations for Q1 2026 came in at 42819000.0, up 28.43% year-over-year; the trailing twelve-month figure through Mar 2026 was 174095000.0 (up 30.08% YoY), and the FY2025 annual result was 190886000.0, up 25.9% from the prior year.
• Income from Continuing Operations came in at 42819000.0 for Q1 2026 at Allogene Therapeutics, down from 39057000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 39057000.0 in Q4 2025 to a low of 97033000.0 in Q1 2023.
• The 5-year median for Income from Continuing Operations is 65169000.0 (2024), against an average of 66326294.12.
• Across the five-year window, Income from Continuing Operations plunged 5046.54% in 2022 and soared 36.6% in 2025, its largest moves.
• Allogene Therapeutics' Income from Continuing Operations stood at 93638000.0 in 2022, then increased by 15.8% to 78844000.0 in 2023, then rose by 27.02% to 57544000.0 in 2024, then surged by 32.13% to 39057000.0 in 2025, then dropped by 9.63% to 42819000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 42819000.0 (Q1 2026), 39057000.0 (Q4 2025), and 41319000.0 (Q3 2025), per Business Quant data.